Teacher Retirement System of Texas Has $274,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Teacher Retirement System of Texas boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 16.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,568 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,363 shares during the period. Teacher Retirement System of Texas’ holdings in Collegium Pharmaceutical were worth $274,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its stake in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 316 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of Collegium Pharmaceutical by 3.0% during the fourth quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock worth $366,000 after buying an additional 374 shares in the last quarter. Gallacher Capital Management LLC boosted its position in Collegium Pharmaceutical by 3.3% during the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock worth $417,000 after acquiring an additional 470 shares during the last quarter. TD Private Client Wealth LLC grew its stake in shares of Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after acquiring an additional 483 shares in the last quarter. Finally, Caprock Group LLC raised its holdings in shares of Collegium Pharmaceutical by 6.7% in the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company’s stock valued at $249,000 after purchasing an additional 543 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages recently commented on COLL. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. Finally, Piper Sandler decreased their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $29.39 on Wednesday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company’s fifty day simple moving average is $30.21 and its 200 day simple moving average is $32.29. Collegium Pharmaceutical, Inc. has a 1-year low of $27.28 and a 1-year high of $42.29. The company has a market cap of $925.37 million, a price-to-earnings ratio of 12.67 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. On average, research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the sale, the chief financial officer now directly owns 177,195 shares of the company’s stock, valued at $5,315,850. This represents a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,193 shares of company stock worth $3,243,594 over the last 90 days. Company insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.